Riskpilot← Back to searchSign inGet full accessDanske Speciallæger ApS
APSActiveCVR 39075946Ferdinand Sallings Stræde 2Medical specialists activities · NACE 8622Est. 201716 employeeswww.dklaeger.dk
Revenue 2025
DKK 14,4M
+9% vs 2024
EBITDA margin
42.6%
+49% vs 2024
Equity ratio
56.3%
Financial strength
Net profit 2025
DKK 4,4M
+45% vs 2024
| Revenue | DKK 14,4M | +9% |
| EBITDA | DKK 6,1M | +49% |
| Net profit | DKK 4,4M | +45% |
| Total assets | DKK 9,6M | +45% |
| Equity | DKK 5,4M | +21% |
| Employees | 16 | — |
Legal name
Danske Speciallæger ApS
CVR number
39075946
Legal form
Anpartsselskab
NACE code
8622 · Medical specialists activities
Founded
9. november 2017
Share capital
DKK 50.000
Employees
16 (FTE)
VAT registered
Yes
Audit selected
Yes
Last report
2025-12-31
Financial year
January – December
Signatory rights
Selskabet tegnes af én direktør.
Company purpose
Selskabets formål er at drive lægevirksomhed, herunder sundhedskonsultationer for diverse aktører, andre private øjne og øre-næse-hals læger, samt optikere og hermed efter ledelsens skøn beslægtet virksomhed.
Address
Ferdinand Sallings Stræde 2
Phone
+4582131226
Email
kontakt@dklaeger.dk
Website
www.dklaeger.dk
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 2.206 | 3.867 | 8.206 | 13.180 | 14.407 |
| Staff expenses | -916 | -561 | -4.217 | -9.057 | -8.277 |
| EBITDA | 1.290 | 3.307 | 3.990 | 4.123 | 6.131 |
| Depreciation & amort. | -10 | -23 | -117 | -260 | -555 |
| EBIT | 1.280 | 3.284 | 3.873 | 3.863 | 5.576 |
| Net financials | 104 | 28 | 65 | 58 | 130 |
| Profit before tax | 1.384 | 3.312 | 3.938 | 3.921 | 5.706 |
| Tax | 303 | 724 | 874 | 866 | 1.263 |
| Net profit | 1.081 | 2.587 | 3.064 | 3.055 | 4.443 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 1.834 | 2.766 | 6.783 | 6.643 | 9.630 |
| Equity | 1.227 | 1.864 | 4.928 | 4.483 | 5.425 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 603 | 898 | 1.753 | 2.025 | 4.113 |
| Total debt | 603 | 898 | 1.753 | 2.025 | 4.113 |
EBITDA margin
42.6%
This company
15.8%
Market median
+170% vs market
20212025
Equity ratio
56.3%
This company
38.2%
Market median
+47% vs market
20212025
Return on equity
81.9%
This company
18.4%
Market median
+345% vs market
20212025
Net profit margin
30.8%
This company
8.1%
Market median
+280% vs market
20212025
Asset turnover
1.50×
This company
1.12×
Market median
+34% vs market
20212025
Debt / equity
0.77×
This company
0.62×
Market median
+24% vs market
20212025
- Annual report 2025Filed via CVR / Virk · Period 2025-01-01 – 2025-12-31
- Annual report 2024Filed via CVR / Virk · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via CVR / Virk · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via CVR / Virk · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via CVR / Virk · Period 2021-01-01 – 2021-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
DV Management | Management | 2017 |
| Former (1) | ||
SA Management | Management | 2017 – 2018 |
No data on file.
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 100% | 100% | 2018 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Dr. Danson Holding ApS
Danske Speciallæger ApS Board members of Danske Speciallæger ApS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Danson Vasanthan Muttuvelu | Management | 0 companies |
| Suzan Al Kole | Management | 0 companies |